Young S Lee

Gemcitabine and cisplatin plus durvalumab with or without tremelimumab in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, single-centre, phase 2 study.

M. Rebelatto, J. W. Kim, P. Mccoon, 2022, The lancet. Gastroenterology & hepatology.

Circulating Tumor DNA Identifies Diverse Landscape of Acquired Resistance to Anti–Epidermal Growth Factor Receptor Therapy in Metastatic Colorectal Cancer

H. Feilotter, D. Tu, H. Kennecke, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Impact of consensus molecular subtyping (CMS) on survival in the CO.26 trial of durvalumab plus tremelimumab versus best supportive care (BSC) in metastatic colorectal cancer (mCRC).

H. Feilotter, D. Tu, S. Kopetz, 2022, Journal of Clinical Oncology.

Phase II study assessing tolerability, efficacy, and biomarkers for durvalumab (D) ± tremelimumab (T) and gemcitabine/cisplatin (GemCis) in chemo-naïve advanced biliary tract cancer (aBTC).

M. Rebelatto, J. W. Kim, D. Oh, 2020 .

Integrating Genomics into Drug Discovery and Development: Challenges and Aspirations

Song Wu, S. Sridhar, B. Jallal, 2017, Pharmaceutical Medicine.

Tissue and plasma tumor mutation burden (TMB) as predictive biomarkers in the CO.26 trial of durvalumab + tremelimumab (D+T) versus best supportive care (BSC) in metastatic colorectal cancer (mCRC).

H. Feilotter, D. Tu, H. Kennecke, 2021 .